Novartis Trileptal Has Fewer Hemopoietic, Dermatologic AEs Than Tegretol
Executive Summary
Novartis' Trileptal labeling indicates that the anticonvulsant may be associated with fewer serious hemopoietic and dermatologic adverse events than the company's older antiseizure drug Tegretol.
You may also be interested in...
Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.
Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.
Zonegran Postmarketing Skin/Renal AEs To Be Considered Unlabeled Events
Elan should consider any postmarketing reports of allergic, skin, blood disorder and renal reactions with its new antiepileptic Zonegran to be unlabeled events, FDA told the company.